Bayer to Present Finerenone Clinical Trial Results

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia  (finerenone) clinical trial program at the European Renal Association (ERA) 62^nd Congress scientific sessions in Vienna, Austria.

KERENDIA is currently approved to reduce the risk of cardiovascular death, hospitalization for heart failure (HF), non-fatal myocardial infarction (MI), sustained eGFR decline, and end-stage kidney disease in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).¹

Data being presented at ERA include:

• Effect of Finerenone on eGFR Slope Across Different Levels of Baseline Albuminuria: Insights from FINEARTS-HF
• THE COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a UACR Endpoint (CONFIDENCE) TRIAL: Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes
• Changes in Albuminuria and The Effect of Finerenone on Cardiovascular Outcomes: Insights from FINEARTS-HF

For more information, go to www.bayer.com.

1. Bayer Pharmaceuticals. Kerendia (finerenone) [package insert]. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf. Accessed June 2, 2025.